Company Monitoring Page for Biogen

latest headlines for company on cafepharma

Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers
Fierce Pharma
Thu, 08/17/17 - 11:48 pm
Tags:
multiple sclerosis, MS, drug pricing, Bayer, Biogen, Merck KGaA, Novartis, Sanofi, Teva Pharmaceutical, Roche
Biogen gains over 1 billion in capitalization thanks to Alzheimer’s pipeline
GoInPharma
Thu, 08/17/17 - 11:47 pm
Tags:
Biogen, Alzheimer's disease, aducanumab
Biogen, Merck use predictive modeling to better negotiate value-based contracts
Medical Marketing and Media
Tue, 08/15/17 - 10:05 am
Tags:
Biogen, Merck, predictive modeling, value-based drug pricing, value-based contracts
The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results
Fierce Pharma
Thu, 08/10/17 - 06:58 pm
Tags:
pharma stocks, Merck, Pfizer, AbbVie, Eli Lilly, Bristol-Myers Squibb, GSK, Roche, Sanofi, Bayer, Novo Nordisk, Celgene, Biogen, AstraZeneca
These 3 Biotechs Just Crushed Analyst Expectations
Motley Fool
Mon, 08/7/17 - 01:36 pm
Tags:
biotech, earnings, Sarepta Therapeutics, Biogen, Gilead Sciences
Spinraza launch set for blockbuster trajectory
BioPharma Dive
Wed, 07/26/17 - 12:11 am
Tags:
Spinraza, Biogen, SMA, spinal muscular atrophy
Biogen, Opening Bottlenecks, Sees Spine Drug Sales, Shares Rise
Xconomy
Tue, 07/25/17 - 08:37 am
Tags:
Biogen, earnings
Biogen lays out a plan to “streamline” ops and add $400M to fund neurosciences R&D, growth
Endpoints
Tue, 07/25/17 - 08:29 am
Tags:
Biogen, R&D, restructuring
Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN
Yahoo/Zacks.com
Mon, 07/24/17 - 11:14 am
Tags:
earnings, Eli Lilly, Biogen, Amgen
These 5 Drugs Could Be Worth $45 Billion -- and They're Not Even on the Market Yet
Motley Fool
Sun, 07/23/17 - 11:47 am
Tags:
Biogen, aducanumab, JNJ, apalutamide, Eli Lilly, abemaciclib, AbbVie, Rova-T, Celgene, ozanimod
Biotechs Find Strength In Numbers In Treating Multiple Sclerosis
Investors Business Daily
Fri, 07/21/17 - 10:25 am
Tags:
MS, multiple sclerosis, Roche, Celgene, Novartis, Biogen, ozanimod, Gilenya, Ocrevus, Extavia
For Biogen's Spinraza launch, things are looking up on the coverage front: analyst
Fierce Pharma
Thu, 07/20/17 - 10:11 am
Tags:
Biogen, Spinraza, drug launches, spinal muscular atrophy, SMA
How Biogen Inc. Makes Most of Its Money
Motley Fool
Thu, 07/13/17 - 05:43 pm
Tags:
Biogen, Tecfidera, Tysabri, MS, multiple sclerosis
EMA Restricts Use of Biogen MS Drug
RAPS.org
Sun, 07/9/17 - 11:39 am
Tags:
Europe, EMA, Biogen, MS, multiple sclerosis, Zinbryta
Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul
Bloomberg
Fri, 07/7/17 - 10:31 am
Tags:
rare disease, healthcare reform, Shire, Jazz Pharmaceuticals, Sanofi, Roche, Biogen, Alexion, Vertex Pharmaceuticals
PTC and Roche report solid data for Spinraza rival
BioPharma Dive
Wed, 07/5/17 - 06:55 pm
Tags:
PTC Therapeutics, Roche, Spinraza, Biogen, RG7916, SMA, spinal muscular atrophy
Biogen aims to block Tecfidera generics with flurry of lawsuits
Bizjournals.com
Tue, 07/4/17 - 11:22 pm
Tags:
Biogen, Tecfidera, generics, MS, multiple sclerosis, Novartis, Sandoz, Mylan Labs
The 9 Best-Selling Prescription Drugs in 2016 (Each One Topped $6 Billion)
Motley Fool
Fri, 06/30/17 - 11:06 am
Tags:
prescription data, Sanofi, Lantus, Roche, Herceptin, Avastin, Celgene, Revlimid, JNJ, Merck, Remicade, Biogen, Rituxan, Amgen, Enbrel, Gilead Sciences, Harvoni, AbbVie, Humira
2 Pharma Buyout Targets That May Surprise You
Motley Fool
Tue, 06/27/17 - 09:46 am
Tags:
Biogen, Bristol-Myers Squibb, M&A, MS, multiple sclerosis, immuno-oncology
EMA Recommends New HCV, Cancer and MS Drugs for Approval
RAPS.org
Sat, 06/24/17 - 09:11 am
Tags:
Europe, EMA, hepatitis C, multiple sclerosis, breast cancer, renal cell carcinoma, AbbVie, Maviret, Gilead Sciences, Vosevi, Biogen, Amgen, Samsung Bioepis, biosimilars, Humira, Novartis, Kisqali, EUSA, Fotivda

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.